Citations

Showing 10 of 108162 citations.

Patients with POEMS Syndrome Have High Bone Turnover and Increased Circulating Angiogenic Cytokines; Should Angiopoietin-2 and Bone-Specific Alkaline Phosphatase Be Used As Minor Criteria for the Diagnosis of the Disease?
Terpos, Evangelos , Harel, Stéphanie , Christoulas, Dimitrios, Fermand, Jean Paul, Terpos, Evangelos , Dimopoulos, Meletios Α. , Buadi, Francis K. , Voskaridou, Ersi , Kastritis, Efstathios , Dispenzieri, Angela

Mayo Clinic

Blood | October 14, 2019 | Volume: 118 | Issue: 21 | Pages: 806-806

10.1182/blood.v118.21.806.806 Get It

Abstract Abstract 806FN2 POEMS syndrome is defined by the presence of peripheral neuropathy (P), monoclonal plasma cell disorder (M), organomegaly (O), endocrinopathy (E) and skin changes (S). The majority of patients have sclerotic bone lesions, although the underlying mechanisms are still unclear. Increased circulating vascular endothelial growth factor (VEGF) is another feature of the disease. However, there is almost no information on the role of other angiogenic molecules in POEMS biology. The aim of the study was to evaluate bone metabolism and angiogenic cytokines in POEMS and compare the results with multiple myeloma (MM) and osteosclerotic patients of other etiology. We retrospectively studied 61 POEMS patients (40M/21F, median age 52 years) who were diagnosed between 1996 and 2010 and were treated and followed in Mayo Clinic Rochester (MN, USA), Hôpital Saint-Louis, Paris (France) and in Alexandra Hospital, Athens (Greece). We evaluated the following indices of bone remodeling and angiogenesis in all patients at diagnosis and in 22 of them one month after front-line treatment: i) osteoclast regulators [sRANKL and osteoprotegerin (OPG)]; ii) osteoblast inhibitor dickkopf-1 (Dkk-1); iii) bone resorption marker CTX; iv) bone formation markers [bone-specific alkaline phosphatase (bALP) and osteocalcin]; and v) angiogenic cytokines [VEGF, angiogenin (ang), angiopoietin (angp)-1 and -2]. These molecules were also measured in 60 newly diagnosed, untreated MM patients (34M/26F, median age: 54 years) and 44 healthy controls. Bone markers were also evaluated in 24 patients with HbS/beta-thalassemia (10M/14F, median age: 43 years) who presented with osteosclerosis, defined as osteosclerotic bone lesions in plain radiography and high T-score of lumbar spine DXA (median: +3.6, range: +2 to +7.9). All POEMS patients presented with P and M, while 90% had E, 83% had S, 61% had O and 32% had papilloedema. One or more documented sclerotic bone lesions in plain X-rays were observed in 78% of patients (diffuse lesions in 44%), while 43% of patients had also an osteolytic component. Seven patients had Castleman disease. At diagnosis, compared to controls, POEMS patients had increased levels of bALP (mean ± SD: 48.3 ± 22.9 IU/L vs. 21.6 ± 8.2 IU/L; p<0.001), CTX (0.97 ± 0.94 ng/ml vs. 0.33 ± 0.24 ng/ml; p<0.001), Dkk-1 (p<0.001), sRANKL (p<0.001) and sRANKL/OPG ratio (p<0.001). Patients with diffuse osteosclerosis had increased levels of Dkk-1 compared to others (p = 0.05), suggesting a balance effect to increased formation activity. Patients with POEMS had increased levels of bALP and decreased levels of CTX compared to MM patients (p<0.001 and p = 0.03, respectively), while they had increased levels of CTX and sRANKL/OPG ratio compared to HbS/beta-thal patients (p = 0.001 for both comparisons). There were no other differences regarding bone markers among studied groups. Regarding angiogenic cytokines, at diagnosis, POEMS patients had elevated VEGF (1232 ± 565 pg/ml vs. 195 ± 211 pg/ml; p<0.001), ang (266 ± 82 ng/ml vs. 190 ± 45; p<0.001) and angp-2 (3.5 ± 2.2 ng/ml vs. 1.2 ± 0.6 ng/ml; p<0.001) and decreased angp-1 (p =0.05) and angp-1/angp-2 ratio (reflects increased angiogenic capacity; 9.1 ± 8.8 vs. 44.8 ± 76.1; p<0.001) compared to normal controls. We found no strong correlations between the levels of VEGF, ang and angps. When compared to MM patients, POEMS patients had increased circulating VEGF (p = 0.001) without any difference regarding the other angiogenic cytokines. Response to therapy was accompanied by a dramatic reduction of VEGF only (551 ± 541 pg/ml compared to baseline 1800 ± 1510 pg/ml; p = 0.003). Receiver-operating characteristic (ROC) curve analysis showed that high levels of angiopoietin-2 (≥ 2.3 ng/ml) and high bALP (≥ 38 IU/l) each have a 95% specificity for patients with POEMS syndrome. These results suggest that patients with POEMS syndrome have high bone turnover with increased bone formation as compared to healthy subjects, to MM patients, who have reduced bone formation, and to osteosclerotic HbS/beta-thal patients, who have diminished bone resorption. Importantly, our analysis supports the use of angp-2, bALP along with VEGF as minor criteria for the diagnosis of POEMS. Successful treatment reduced VEGF, which seems to be a suitable marker for the follow-up of POEMS patients. Furthermore the imbalance of angp-1/angp-2 pathway may indicate possible targets for the development of novel agents against POEMS. Disclosures: No relevant conflicts of interest to declare.
Chronic Lymphocytic Leukemia Patients with IGHV Genes Carrying Only Silent Mutations Have A Longer Time From Diagnosis to Initial Therapy Than Patients Expressing B-Cell Receptors with No Somatic Mutations
Kaufman, Matthew, Yan, Xiao‐Jie , Rassenti, Laura Z., Oscier, David , Davi, Frédéric , Belessi, Chrysoula, Davis, Zadie , Byrd, John C. , Brown, Jennifer R. , Rai, Kanti R., Ghia, Emanuela M. , Neuberg, Donna , Σταματόπουλος, Κώστας , Ghia, Paolo , Rosenquist, Richard , Agathangelidis, Andreas , Kay, Neil E. , Rai, Kanti R., Kipps, Thomas J. , Chiorazzi, Nicholas

Mayo Clinic

Blood | October 14, 2019 | Volume: 118 | Issue: 21 | Pages: 288-288

10.1182/blood.v118.21.288.288 Get It

Abstract Abstract 288 BACKGROUND. Chronic lymphocytic leukemia (CLL) patients with mutated IGHV genes (M-CLL) have better outcomes than patients with unmutated IGHV genes (U-CLL). It has been proposed that this difference reflects the fact that IGHV mutations alter the structure of the B-cell antigen receptor (BCR) such that it no longer binds stimulatory (auto) antigens and therefore cannot deliver trophic signals to the leukemic cells. For this theory to be correct, only replacement (R) mutations and in particular non-conservative R mutations that would more likely alter amino structure of the IGHV/D/J rearrangements would have relevance. Silent (S) mutations by definition do not change amino acid structure and could not alter antigen binding. We sought to investigate this hypothesis by analyzing the types (S, conservative R, non-conservative R) and distribution of mutations that occur in IGHVs of M-CLL clones and then comparing the time to first therapy (TTFT) in patients with different IGHV features. This analysis expanded an initial study of 1569 CLL cases in the US to include 1858 patients from Europe for a total of 3427 cases. METHODS. Using IGMT software and tools, we analyzed the rearranged IGHV sequences of 3427 cases and characterized their mutations in several respects: first, if IGHV mutations altered amino acid structure (S vs. R); second, if mutations occurred in CDRs (antigen binding domains) or FRs (scaffolds of the BCR); third, if R mutations were conservative or non-conservative as determined by charge, hydropathy, and size. TTFT for patients was examined with various combinations of the above parameters. Differences in TTFT were estimated by the method of Kaplan and Meier and assessed using the log rank test. RESULTS. First, TTFT was compared for 4 groups of patients with the following mutation profiles: no mutations; only S mutations (median 1 per sample); only R mutations (median 1 per sample); and mixed S and R mutations (median 16 per sample). These 4 categories were significantly different (P<0.0001), with the median TTFT being 2.0 yrs for no mutations; 2.6 yrs for R only; 2.8 yrs for S only; and 7.3 yrs for mixed. All comparisons used patients with no mutations (n=1234) as the reference group. We identified statistically longer TTFT (2.8 vs 2.0 yrs; P=0.04) in patients with only S mutations (n=62). Patients with only R mutations (n=218) also had superior outcomes (2.6 yrs vs. 2.0 yrs; P=0.008). There was no statistical significance in TTFT between patients with all S vs. all R mutations (2.8 yrs vs. 2.6 yrs; P=0.71). Because exploring the relevance of BCR structural change on TTFT required us to focus on a small subset of patients with only silent IGHV mutations, our sample size was small. Therefore, we expanded the group to include IGHVs with R mutations limited to the FR region (S + R in FR only; n=241) since these mutations would be unlikely to have a major impact on BCR structure, particularly sparing the binding site. When compared to patients with no mutations, this group demonstrated a significantly longer TTFT (2.8 yrs vs. 2.0 yrs, P=0.0002). This finding was upheld when not permitting any non-conservative R mutations in this group, leaving only patients with S plus conservative R mutations in FRs only (n=124); TTFT in this case was 2.8 yrs vs. 2.0 yrs, respectively (P=0.0006). CONCLUSIONS. Our findings show that patients with only S mutations have better outcomes than patients with no mutations, suggesting that a change in BCR structure that could lead to a loss of antigen binding is an unlikely reason for improved clinical course. This is further supported by the finding that the combination of only S plus conservative R mutations located solely in FRs, which probably would not result in major BCR structural changes and therefore antigen binding, is associated with a lengthened TTFT. Therefore, we suggest that the currently accepted paradigm to explain the enhanced survival of M-CLL patients needs to be re-evaluated. Disclosures: Brown: Calistoga: Consultancy, Research Funding; Celgene: Honoraria, Research Funding; Genzyme: Research Funding; GSK: Research Funding. Kipps:Igenica: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Research Funding; Abbott Industries: Research Funding; Pharmacyclics: Membership on an entity's Board of Directors or advisory committees; Genentech: Research Funding; GSK: Research Funding; Gilead Sciences: Consultancy, Research Funding; Amgen: Research Funding.
Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the
Lust, John A., Lacy, Martha Q. , Zeldenrust, Steven R., Greipp, Philip R., Kumar, Shaji , Moon‐Tasson, Laurie L., Donovan, Kathleen A., Dispenzieri, Angela , Gertz, Morie A. , Witzig, Thomas E. , Rajkumar, S. Vincent

Mayo Clinic

Blood | October 14, 2019 | Volume: 118 | Issue: 21 | Pages: 2945-2945

10.1182/blood.v118.21.2945.2945 Get It

Abstract Abstract 2945 Background: We have previously reported on a Phase II trial using IL-1Ra and dexamethasone, in patients with SMM/IMM, showing that IL-1Ra targets the myeloma proliferative component which parallels a decrease in the C-reactive protein, a surrogate for IL-6 production. (Mayo Clinic Proceedings 84 :114 (Feb. 2009)). In early stage myeloma, IL-6 is a central myeloma growth factor and we have shown that abnormal production of IL-1 β in the myeloma microenvironment stimulates the generation of paracrine IL-6. These patients are the individuals most likely to benefit from anti-cytokine therapy in an attempt to delay/prevent the development of active myeloma. We now present updated results of this study including survival data. Methods: Patients that had ≥ 10% bone marrow plasma cells and/or an IgG or IgA M-spike ≥ 3 g/dL and did not require immediate chemotherapy were eligible. All patients received 100 mg of Anakinra (IL-1Ra) SQ qd for 6 months. Patients with evidence of reduction in M-protein levels continued receiving IL-1Ra alone. Patients with stable disease at 6 months or those with a rising M-protein before 6 months received low dose dexamethasone (20 mg qweek) in addition; the dose was adjusted based on response/toxicity. Results: Data were available on 47 patients based on intent to treat, and pts were classified as smoldering (72%) vs. indolent (28%). All SMM patients were in Group 1 or 2 and thirty-eight patients (81%) had greater than 20% bone marrow plasma cells. All 47 patients received IL-1Ra initially and 25/47 subsequently received IL-1Ra/Dex. Seven patients had a decrease in the plasma cell labeling index (PCLI) on IL-1Ra alone which paralleled a decrease in the high sensitivity C-reactive protein (CRP) in all cases. Three patients achieved a minor response to IL-1Ra alone and 9 patients achieved a PR/MR after addition of dexamethasone. For the group of 47 patients, the median progression-free survival was 45 months and the median overall survival has not been reached. When patients were grouped into whether they exhibited a reduction in the C-reactive protein from baseline after 6 months of therapy, the median PFS for patients without (21 patients) or with (26 patients) a greater than one-third reduction in baseline CRP was 1 year vs more than 8 years (p<.01). Similarly, the median OS for patients without or with a reduction in baseline CRP was 7.9 years vs. median not reached (p=.02; see Figure). Toxicity included injection site reactions during the first month of therapy in 86% of patients. Grade 3–4 adverse events consisted mainly of asymptomatic neutropenia (17% of patients) and infection (18% of patients). Patients that progressed to active MM have been treated with standard therapies including lenalidomide, bortezomib, transplant, and novel therapies. In contrast, seven of the 26 patients with a CRP decrease continue with stable disease and minimal toxicity on IL-1Ra alone or in combination with standard agents. Conclusion: The above results suggest that agents such as IL-1Ra that specifically inhibit paracrine IL-6 production are effective at targeting the proliferative myeloma component and warrant further investigation in combination with standard myeloma therapies. Combination therapy that effectively targets both the proliferative and the IL-1 producing myeloma components may be useful in patients with active myeloma that have an elevated growth rate at diagnosis. Disclosures: Lust: Mayo Clinic: Patents & Royalties. Off Label Use: IL-1Ra use in smoldering myeloma. Donovan:Mayo Clinic: Patents & Royalties.
Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis
Wadleigh, Martha , Seymour, John F. , To, Luen Bik, Zhu, Huan J., Komrokji, Rami S. , Roberts, Andrew W. , Mesa, Ruben A.

Mayo Clinic

Blood | October 14, 2019 | Volume: 118 | Issue: 21 | Pages: 282-282

10.1182/blood.v118.21.282.282 Get It

Abstract Abstract 282 Background: The JAK2V617F mutation has been linked to the pathogenesis of myeloproliferative neoplasia. Pacritinib (SB1518) is a potent inhibitor of both wild-type JAK2 and the JAK2V617F mutant. In previously reported Phase 1 studies, patients with myelofibrosis (MF) who received pacritinib achieved steady-state plasma levels above the IC50 for JAK2 at all doses (100–600 mg/d). Target inhibition, measured by phosphorylation of the STAT3, STAT5, and JAK proteins in PBMCs and whole blood was also shown at all doses. 400 mg/d was chosen as the recommended dose (RD) for Phase 2 study. Aim: The primary endpoint of the Phase 2 study was to assess the spleen response rate, defined as a ≥35% reduction in MRI-measured spleen volume between baseline and Week 24. Methods: Qualifying patients had primary, post-ET, or post-PV MF, with palpable splenomegaly ≥5 cm below the left costal margin. Based on minimal myelosuppression in the Phase 1 trials, no minimum hematology values were required for eligibility. Treatment with pacritinib was on a continuous oral, daily schedule. Disease symptoms were evaluated using the MF-SAF. Results: Patients: Thirty-four MF patients (median age 69; range, 44–84 years) consented and were enrolled, of which 25 (74%) were men. Median PS was 1 with 2 patients having PS >1. Median baseline hemoglobin and platelet count were 10.2 g/dL and 119,000/μL, respectively. Fifteen patients (44%) had platelet counts <100,000/μL, including 7 with counts <50,000/μL. Median baseline spleen size was 14 cm (range 4–30 cm) below the LCM by physical exam, and median spleen volume was 2647 cc (range 404–7817 cc) by MRI. Twenty-six patients (76%) were JAK2V617F mutation-positive. The median time on study is 8.2 months (range, 0.5 to 12.1 months). Safety: Seventeen patients (50%) have discontinued, including 8 (24%) due to AEs (1 each for nausea, sepsis, increased bilirubin, subdural hematoma, allergic reaction, GI bleed, and 2 due to thrombocytopenia), 5 for disease progression and 2 for lack of response. Of the AEs leading to discontinuation, only increased bilirubin, allergic reaction and intermittent nausea were considered possibly drug related. Ten patients required dose reduction for adverse events. One patient required drug discontinuation associated with decreased neutrophils and platelets. This was considered related to worsening disease; otherwise, there were no changes in pacritinib dosing related to impaired hematopoiesis. The most common treatment-related AEs were gastrointestinal, which were generally low grade and easily managed. GI AEs >Grade 2 included Grade 3 diarrhea in 2 patients (6%). Only 1 patient discontinued for GI toxicity. Efficacy: Pacritinib produced meaningful reductions in splenomegaly. Thirty patients (88%) showed reductions in palpable splenomegaly; 15 (44%) showed decreases of ≥50% and 6 (18%) achieved clinical resolution of splenomegaly. Eleven patients (32%) had a ≥35% reduction in splenic volume as measured by MRI. Splenic reduction of 50% by PE correlated with a 25% reduction in spleen volume by MRI. Fourteen patients (41%) had reduction in splenic volume by >25%. Spleen response rates were equivalent among patients with low baseline platelet counts and those with normal baseline counts. All spleen responses are ongoing; consequently a median duration of response has not been reached. Two patients met IWG-MRT criteria for clinical improvement in hemoglobin including 1 who became transfusion independent. At the 6-month visit, a significant reduction (>2 point improvement) was observed for MF-associated symptoms, including abdominal pain, bone pain, early satiety, worst fatigue, inactivity, night sweats and pruritus. Conclusions: Pacritinib shows promising efficacy in alleviating MF-associated splenomegaly and constitutional symptoms at a dose that induces minimal myelosuppression. Once-daily dosing is well tolerated, with manageable GI toxicity as the main side effect. Given the lack of myelosuppression with pacritinib, this JAK2 inhibitor is of particular importance for MF patients with impaired hematopoiesis. Disclosures: Mesa: SBIO: Research Funding.
Patterns of Care for Patients with Chronic Lymphocytic Leukemia (CLL): The Connect® CLL Disease Registry
Sharman, Jeff P. , Flowers, Christopher R. , Weiss, Mark A. , Grinblatt, David L. , Lamanna, Nicole , Kozloff, Mark, Swern, Arlene S., Street, Thomas K., Keating, Michael J. , Farber, Charles Michael , Kay, Neil E. , Kipps, Thomas J. , Pashos, Chris Leo , Flinn, Ian W. , Lerner, Susan A. , Sullivan, Kristen A

Mayo Clinic

Blood | October 14, 2019 | Volume: 118 | Issue: 21 | Pages: 2864-2864

10.1182/blood.v118.21.2864.2864 Get It

Abstract Abstract 2864 Introduction: Clinical trials have illuminated a number of unique treatment strategies for patients with CLL. The impact of these strategies on routine practice remains unknown as trial participants may not reflect the same population encountered outside of a clinical trial setting. Many questions remain regarding the sequencing of therapies based on age and performance status. By characterizing current patterns of care; patients, treating physicians, and regulatory agencies will be able to understand the current landscape of CLL treatment. The Connect® CLL registry was designed to report the natural history and real world management of patients receiving therapy for CLL. In this first report, we characterize the therapeutic approaches used for the treatment of patients with CLL of different age groups (i.e. < 65 years, 65–75 years, and ≥ 75 years) and with an ECOG PS status score of 0 compared to 1 or greater. Methods: Connect® CLL is a prospective, longitudinal, observational, multi-center registry conducted in community and academic research centers in the United States. At present, 237 sites are actively participating with a projected study enrollment of 1500 patients. Eligible patients are to be enrolled within 2 months of being initiated on any line of therapy; whether initial therapy or salvage therapy. Each patient will be followed for up to 60 months. Clinical data, physician choices, patient-reported health-related quality of life, response and survival are to be collected approximately every 3 months during participation. Results: A total of 607 patients have been enrolled (4% from academic sites) with a median age of 70 years. 198 were < 65 years old (age group 1), 187 were between 65–75 years old (age group 2), and 222 were ≥ 75 years old (age group 3). ECOG status varied across the three age groups, with an ECOG status score of ≥ 1 for 39%, 52%, and 70% of patients respectively. Treatment patterns varied across the age groups and by ECOG status in the 496 patients reporting therapies. The most commonly recorded first-line regimens independent of age included fludarabine (F) cyclophosphamide (C) and rituximab (R) (33%), bendamustine (B) +/− R (19%), F +/− R (15%), or investigational therapy (15%). For second-line regimens and beyond, the most frequently recorded regimen was B +/− R (30%), FCR (23%), other F-based regimens (13%), or investigational therapy (8%). The use of FCR for first-line treatment decreased significantly with increasing age group, (45%, 32%, 20%, for age group 1, 2, 3 respectively, p=0.04, spearman correlation) while use of F +/− R remained level across the age groups (14%, 15%, 15%, respectively). Compared to age group 1, first-line therapy with B +/− R in age groups 2 and 3 (15%, 22%, 21%, respectively) was higher but did not achieve statistical significance. B +/− R represented the most common treatment for all age groups (37%, 26%, 29%, respectively) as second line therapy but did not vary by age (P=0.35). The use of chlorambucil was infrequent in all age groups, but was more common in age group 3 patients compared to the others (P=0.01), in both first-line (2%, 4%, 12%, respectively) and subsequent lines of therapy (0%, 1%, 8%, respectively). Treatment assignments did not vary by ECOG PS score for patients in age group 1. First-line therapy for patients with an ECOG PS score of 0 in age groups 2 and 3 consisted of FCR (32% and 15%, respectively), F +/− R (19% and 15%, respectively), B +/− R (16% and 15%, respectively), and alkylating agents (3% and 23%, respectively). Patients in age groups 2 and 3 with ECOG PS score ≥ 1 received B +/− R regimen (33% and 22%, respectively), FCR (23% and 21%, respectively), F +/− R (14% and 10%, respectively) and alkylating agents (7% and 9%, respectively) as first-line therapy. Further description and clarification on the various treatment regimens based on the three age groups and by ECOG PS score will be presented at the meeting. Conclusion: The Connect® CLL Registry is the largest prospective, multicenter registry in the United States evaluating management for patients with CLL. With the currently available data, we characterize the extent to which age and performance status are associated with treatment selection in both first-line and subsequent lines of therapy in routine practice. As enrollment increases and additional follow-up is completed, the data will provide more extensive and real world overview of the current treatment strategies used in CLL patients. Disclosures: Sharman: Celgene - consulting: Consultancy; Pharmacyclics: Honoraria; Calistoga: Honoraria; Portola pharmaceuticals: Consultancy. Flowers:Consultancy: Celgene, Prescription Solutions, Spectrum (future), Seattle Genetics, Millennium (future), Genentech (unpaid): Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding. Weiss:Celgene: Consultancy. Grinblatt:Celgene: Honoraria, Speakers Bureau. Kay:Genenetech, Celgene, Hospira,: Research Funding. Kipps:Igenica: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Research Funding; Abbot Industries: Research Funding; Pharmacyclics: Membership on an entity's Board of Directors or advisory committees; Genentech: Research Funding; GSK: Research Funding; Gilead Sciences: Research Funding; Amgen: Research Funding. Lamanna:Celgene Corporation: Advisory board. Pashos:United BioSource Corporation: Research Funding. Flinn:Celgene: Research Funding. Kozloff:Celgene: Consultancy. Lerner:Celgene Connect: Membership on an entity's Board of Directors or advisory committees. Swern:Celgene: Employment. Sullivan:Celgene: Employment. Street:Celgene: Employment. Keating:Celgene Connect: Membership on an entity's Board of Directors or advisory committees.
A Phase I Trial of Zevalin Radioimmunotherapy with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM)
Lacy, Martha Q. , Laumann, Kristina, LaPlant, Betsy, Kumar, Shaji , Hayman, Suzanne R. , Ansell, Stephen M. , Gastineau, Dennis A. , Inwards, David J. , Micallef, Ivana N. , Porrata, Luis F. , Johnston, Patrick B. , Litzow, Mark R. , Dispenzieri, Angela , Gertz, Morie A. , Buadi, Francis K. , Dingli, David , Hogan, William J. , Witzig, Thomas E.

Mayo Clinic

Blood | October 14, 2019 | Volume: 118 | Issue: 21 | Pages: 3095-3095

10.1182/blood.v118.21.3095.3095 Get It

Abstract Abstract 3095 Background: Although HDM is the standard conditioning for pts with MM undergoing ASCT, it is not sufficient for cure. In an effort to improve upon this standard, we added escalating doses of Y-90 Zevalin (a murine IgG1 kappa monoclonal antibody Ibritumomab conjugated to Y-90) to HDM in a standard 3+3 phase I trial design. Y-90 is a beta-emitting radioisotope with a path length of 5 mm allowing it to target CD20+ cells and bystander cells within 5 mm. Methods: Eligibility included being a candidate for ASCT. Consenting patients (pts) received: day -22, rituximab 250 mg/m2 with In2B8 for scanning; day -14, rituximab 250 mg/m2 with escalating doses of Y90-Zevalin; day -2 and -1, melphalan 100 mg/m2/day; day 0, at least 2 × 10(6) CD34/kg stem cells; and GM-CSF until ANC engraftment. The 6 dose levels (DL) were (in Gy): 10; 12; 14; 16; 18; and 20. Dose limiting toxicity (DLT) was defined as: sustained pulmonary or liver toxicity (grade3; 96 hours duration or VOD that does not resove by day 30); delayed engraftment (ANC < 500 at day 21 or platelet transfusion dependence at day 35); and non-hematologic grade (gr) 4 toxicity excluding gastrointestinal or constitutional. Responses were according to IMWG criteria. Accrual was between May 2005 and June 2011. Data was frozen as of August 2, 2011. Results: Thirty pts have been accrued: DL1, 3; DL2, 3; DL3, 3; DL4, 6, DL5, 6; DL6, 6. The median age of patients was 59 (range 32, 73), and 70% were male. 60% had ASCT as primary therapy. The other patients were transplanted in chemosensitive relapse (n=3), chemoresistant relapse (n=7), and untested relapse (n=2). Median time from diagnosis to protocol therapy was 10.4 months (range 3.5, 94.3). Five pts had prior radiation therapy, and 11 had prior ASCT. Maximum tolerated dose (MTD) of Zevalin with fixed dose melphalan 200 mg/m2 was DL 5 (18 Gy) which amounted to 168 mCi (124, 182) administered. No DLTs were observed at DL 1, 2, 3, or 5. There was 1 DLT at DL 4, comprising hepatic failure (gr 5) CMV viremia (gr 3), and delayed engraftment, in a 73 yo patient with chemoresistant relapsed disease, and 2 DLTs at DL 6. These DL 6 DLTs included: 1) fatal bowel necrosis (day 12 post ASCT) in a 67 yo patient with relapsed refractory MM and history of CAD, ischemic colitis, DM; and 2) fatal biopsy proven venoocclusive disease (gr 5), which began day 91 post ASCT in a 62 yo patient with primary refractory MM, peri-mobilization S. aureus bacteremia with septic embolic, and line associated venous thrombosis. Overall, gr 3 or higher AEs were observed in 100% of pts. Non-heme gr 4 AEs were seen in: DL1, 1; DL2, 2; DL3, 0; DL4, 1; DL5, 0; DL6, 4. Median time to ANC >=500 and plts>=50 was 11 (range 8, 17) and 15 days (range 11, 89). Confirmed response rates from immediately pre-protocol to best confirmed response were: CR, 5; VGPR, 5; continued VGPR, 4, and continued PR, 7. If one includes best confirmed response from baseline for those patients using transplant as primary consolidation, 4 PRs are upstaged to VGPRs. Median follow-up for all pts is 24.5 months (0.8, 64.8), and 10 pts have died. The median PFS for pts proceeding to early and delayed ASCT was 30.4 months (95%CI 4.1-NR) and 10.3 months (95%CI 2.8–21.7), respectively. The median OS for pts proceeding to early and delayed ASCT was not attained and 11.4 months (95%CI 2.8-NA), respectively. Conclusions: For patients with multiple myeloma, the MTD of Zevalin with fixed high-dose melphalan is 18 Gy. The combination of a VGPR plus continued VGPR rate of 60%, a median PFS of 13.1 months, and a 73% 1 year OS rate make this a regimen worthy of further study. Disclosures: Kumar: Merck: Consultancy, Membership on an entity's Board of Directors or advisory committees.
Outcome of Patients with IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplants: A Retrospective CIBMTR Study.
Reece, Donna , Vesole, David H. , Pérez, Waleska S., Zhang, Mei‐Jie , Shrestha, Smriti, Dispenzieri, Angela , Milone, Giuseppe , Hari, Parameswaran

Mayo Clinic

Blood | October 14, 2019 | Volume: 112 | Issue: 11 | Pages: 3328-3328

10.1182/blood.v112.11.3328.3328 Get It

Abstract Multiple Myeloma (MM) is the most common indication for autologous hematopoietic stem cell transplantation (auto HCT). However, little information is available regarding the outcome of patients (pts) with the rarer immunoglobulin subtypes IgD and IgM, which represent 2% and 0.5%, respectively, of all MM cases. In addition, IgD MM has been reported previously to have a poorer prognosis, at least after conventional therapy. The CIBMTR conducted a retrospective analysis of MM pts transplanted between 1995–2005 to describe the characteristics and results of auto HCT in IgD (n=36) and IgM (n=11) among 3578 MM patients with auto HCT during this period. Median follow-up of survivors was 41 (range 2–130) months for pts with IgD and 58 (range 5–101) months for those with IgM MM. Among pts with IgD subtype, median age was 52 years (yrs), 67% were male, 36% had a creatinine >2 mg/L, 61% had Durie-Salmon stage III disease at diagnosis and 33% had Kappa Serum Light chain; the corresponding values for IgM pts were 58 yrs, 36%, 73% and 55% respectively. Prior to auto HCT, 75% of IgD pts were chemosensitive and 25% had received >2 lines of chemotherapy, while all IgM pts were chemosensitive and none had received more than 2 lines of prior therapy. Median time from diagnosis to auto HCT was 9 months in both subtypes. The most common conditioning regimen was singleagent melphalan, and all but 1 pt with IgD disease were grafted with blood stem cells. The small sample size precluded multivariate analysis for potential prognostic factors for outcome. Below table summarizes the post-auto HCT results in these pts contrasted with a reference pool of IgG and IgA MM receiving auto HCT in the same time period. Outcomes, probability (95% CI) IgD IgM IgG/IgA (n=36) (n=11) (n=1475) 100-day mortality, % 0 9 ( 0 – 32) 7 (5 – 8) Non MM deaths, % @ 1 yr 0 9 (0 – 32) 5 (4 – 7) @ 3 yrs 3 (0 – 13) 21 (2 – 51) 16 (14 – 18) Relapse/ Progression, % @ 1 yr 21 (9 – 37) 20 (2 – 49) 18 (16 – 20) @ 3 yrs 59 (41 – 76) 32 (8 – 64) 36 (34 – 39) Progression-free survival, % @ 1 yr 79 (63 – 91) 71 (41 – 93) 77 (74 – 79) @ 3 yrs 38 (21 – 56) 47 (17 – 78) 47 (44 – 50) Overall survival, % @ 1 yr 87 (74 – 97) 91 (68 – 100) 79 (77 – 85) @ 3 yrs 69 (51 – 84) 68 (36 – 93) 53 (50 – 57) No striking differences are apparent in the post auto HCT outcomes of patients with IgD and IgM MM. These results are also consistent with published outcomes of pts with IgD/ IgM MM (Wechaleker et al Ann Hematol. 2005 Feb; 84(2):115–7; Maisner et al Bone Marrow Transplant. 2008 Jan; 41(1):51–4).
Functional ability is associated with higher adherence to behavioral interventions in mild cognitive impairment
Amofa, Priscilla , DeFeis, Brittany , Wit, Liselotte De , O’Shea, Deirdre , Mejia, Andrea, Chandler, Melanie , Fields, Julie A. , Phatak, Vaishali , Dean, P.M. , Locke, Dona E.C. , Crook, Julia, Smith, Glenn, De Wit, Liselotte , Mejia, Andrea, Dean, Pamela M., Crook, Julia E. , Smith, Glenn E.

Mayo Clinic

The Clinical Neuropsychologist | October 14, 2019 | Volume: 34 | Issue: 5 | Pages: 937-955

10.1080/13854046.2019.1672792 | PMID 31608773 Get It

Phase 1 Study Of The Novel Pan-Pim Kinase Inhibitor LGH447 In Patients With Relapsed/ Refractory Multiple Myeloma
Guenther, Andreas , Lebovic, Daniel, Kumar, Shaji , Song, Dongweon, Xiang, Fang, Hynds, David, Vanasse, K. Gary J., Raab, Marc S. , Ocio, Enrique M. , Thomas, Sheeba K. , Jakubowiak, Andrzej , Xiang, Fang, Goh, Yeow Tee

Mayo Clinic

Blood | October 14, 2019 | Volume: 122 | Issue: 21 | Pages: 3186-3186

10.1182/blood.v122.21.3186.3186 Get It

Abstract Background LGH447 is a novel, specific pan-Pim kinase inhibitor in development for the treatment of patients with multiple myeloma (MM) and other hematologic malignancies. The PIM kinase gene family encodes 3 serine/threonine protein kinases that have roles in cell cycle progression and survival. In human disease, elevated levels of Pim1 and Pim2 are associated with hematologic malignancies, with MM showing the highest level of Pim2 expression. In preclinical studies, a majority of MM cell lines proved sensitive in vitro to LGH447-mediated Pim inhibition, exhibiting a dose-dependent decrease in cell proliferation. Furthermore, LGH447 was well tolerated and demonstrated significant inhibition of tumor growth in xenograft mouse models of MM as compared with control animals, supporting the clinical development of LGH447 in MM patients. Methods Patients with relapsed/refractory MM for whom no effective treatment options exist were enrolled on this first-in-human, multicenter, open-label phase 1 dose-escalation study (CLGH447X2101). Escalating doses of single-agent LGH447 were administered orally on a continuous daily dosing schedule. Treatment continued until disease progression, unacceptable toxicity, consent withdrawal, or death. The primary objective was to estimate the maximum tolerated dose (MTD) of LGH447 administered as a single agent, orally, once daily. Secondary objectives included assessing the safety, tolerability, preliminary antimyeloma activity, and pharmacokinetic (PK) profiles of LGH447. Dose escalation followed a Bayesian logistic regression model based on dose-limiting toxicities (DLTs) occurring in cycle 1. Adverse events (AEs) were graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events v4.03. Efficacy assessments were made by investigators according to International Myeloma Working Group (IMWG) uniform response criteria with modifications. Following determination of the MTD for LGH447, additional patients will be enrolled in an expansion cohort to further characterize the safety and tolerability profile of LGH447. Results At the data cutoff, 19 patients have been treated at the following doses: 70 mg (n = 5), 150 mg (n = 6), 200 mg (n = 4), 250 mg (n = 4), with enrollment ongoing in dose escalation. Median age was 66 years (range, 41-75 years). Most patients (94.7%) presented with baseline Eastern Cooperative Oncology Group performance status 0-1. Most patients (73.7%) had received ≥ 2 prior regimens (median 4; range, 1-11), 89.5% had received prior bortezomib, and 84.2% had received prior lenalidomide and/or thalidomide (68.4% and 47.4%, respectively). Ten patients are ongoing at doses between 150-250 mg, with a median duration of exposure of 6 weeks (range, 1-26.6 weeks), and 9 patients discontinued (disease progression [n = 6], AEs [n = 2], withdrawal of consent [n = 1]). There was 1 DLT consisting of grade 3 thrombocytopenia at the 200 mg dose level and no reported suspected unexpected serious AEs. The majority of AEs regardless of study drug relationship were grade 1/2. Most common grade 3/4 AEs were thrombocytopenia (31.6%), anemia (21.1%), and neutropenia (15.8%). No deaths have occurred on study. LGH447 displayed time-dependent PK with a 3- to 6-fold accumulation from day 1 to steady state (day 14). After a single oral dose, area under the curve and maximum concentration increased somewhat more than in proportion to the dose from 70 to 250 mg. Evidence of single-agent activity, as determined by investigators using IMWG criteria, has been seen in multiple patients, with best response to date being a very good partial response (VGPR). Conclusion In heavily treated patients with relapsed/refractory MM, LGH447 was generally well tolerated and exhibited evidence of single-agent efficacy in multiple patients, validating Pim kinase inhibition as a promising therapeutic rationale and supporting its further clinical development in patients with MM and other hematologic malignancies. Dose escalation is ongoing and updated results will be presented. Disclosures: Ocio: BMS: Consultancy; Arry-520: Consultancy; Pharmamar: Research Funding; Celgene: Honoraria, Research Funding; Onyx: Consultancy, Research Funding; Novartis: Honoraria. Thomas:Novartis: Research Funding; Celgene: Research Funding; Immunomedics: Research Funding; Pharmacyclics: Membership on an entity’s Board of Directors or advisory committees; Onyx: Membership on an entity’s Board of Directors or advisory committees; Millenium: Research Funding. Günther:Novartis: Consultancy, Research Funding. Lebovic:Celgene: Speakers Bureau; Allos/Spectrum: Speakers Bureau; Genentech: Speakers Bureau; Onyx: Speakers Bureau. Kumar:Onyx: Consultancy, Research Funding; Millennium: Consultancy, Research Funding; Celgene: Consultancy, Research Funding. Jakubowiak:Onyx: Consultancy, Honoraria, Speakers Bureau; Millennium: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Speakers Bureau; BMS: Consultancy, Honoraria. Song:Novartis: Employment. Xiang:Novartis: Employment. Hynds:Novartis: Employment. Vanasse:Novartis: Employment. Goh:Jannsen: Research Funding; BMS: Membership on an entity’s Board of Directors or advisory committees; Gilead: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Hospira: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding.
Erythropoiesis Stimulating Agents and the Risk of Leukemic Transformation in Primary Myelofibrosis.
Huang, Jocelin, Li, Chin‐Yang, Hanson, Curtis A. , Pardanani, Animesh , Tefferi, Ayalew , Mesa, Ruben A. , Wu, Wenting

Mayo Clinic

Blood | October 14, 2019 | Volume: 110 | Issue: 11 | Pages: 554-554

10.1182/blood.v110.11.554.554 Get It

Abstract BACKGROUND: Information regarding risk factors for leukemic transformation (LT) in primary myelofibrosis (PMF) is limited, although both leukocytosis and abnormal cytogenetics have previously been implicated. The current retrospective study examines clinical variables at diagnosis as well as specific treatment modalities for their effect on LT in PMF. METHODS: Diagnoses of PMF and LT were based on World Health Organization criteria. In addition, study inclusion required availability, for review, of bone marrow histology and clinical data obtained at or within 6 months of diagnosis but prior to treatment intervention. Statistical methods used were standard and included Cox regression analysis of leukemia-free survival (LFS). RESULTS: A master database of PMF patients seen at the Mayo Clinic from 1976 through 2006 was queried to identify 311 patients who fulfilled the aforementioned stipulated criteria for study inclusion; median age was 57 years and 41% were females. At presentation, 30% of the patients displayed a hemoglobin level (Hgb) of < 100 g/L, 20% a leukocyte count of < 4 or > 30 x 109/L, 18% a platelet count of < 100 x 109/L, 12% an absolute monocyte count (AMC) of ≥ 1 x 109/L, 28% hypercatabolic symptoms and 35% a peripheral blood (PB) blast percentage of ≥ 1; 27 patients (9%) had a PB blast percentage of ≥ 3. Dupriez prognostic scoring system distribution for high, intermediate, and low risk disease was 30 (10%), 94 (30%), and 187 (60%) patients. Among 182 and 139 evaluable patients, 74 (41%) and 80 (58%) displayed cytogenetic abnormalities and JAK2V617F, respectively. At a median follow-up of 27 months (range 0–282), 27 cases (9%) of LT were documented at a median time from diagnosis to LT of 26 months (range 0.8–266). Effect of clinical and laboratory variables at diagnosis on leukemic transformation By univariate analysis, LFS was negatively affected by anemia (p=0.04), leukocytosis (p=0.04), PB monocyte count ≥ 1 x 109/L (p=0.02), platelet count of < 100 x 109/L (p=0.004), hypercatabolic symptoms (p=0.03) and PB blast percentage of ≥ 3 (p<0.0001); LFS was not affected by PB blast percentage of > 1 but < 3 (p=0.49). By multivariable analysis, significance was sustained only for PB blast percentage of ≥ 3 (p = 0.0002) and platelet count of < 100 x 109/L (p = 0.02) with hazard ratios (HR) of 5.8 and 2.8 and 95% confidence intervals (CI) of 2.3–14.6 and 1.2–6.6, respectively. The presence of JAK2V617F did not affect LFS (p=0.98). Effect of specific treatment on leukemic transformation By univariate analysis, LT was significantly associated with history of splenectomy (p=0.01) and treatment with erythropoiesis stimulating agents (ESA; p=0.004), danazol (p=0.007), and androgens (p=0.03) but not with hydroxyurea (p=0.17), interferon alpha (p=0.95), thalidomide (p=0.26) or other drugs. On multivariable analysis, significance was sustained for both ESA (p = 0.005; HR 3.1, CI 1.4–6.8) and danazol (p = 0.01; HR 3.4, CI 1.3–8.5), even when the aforementioned prognostic indicators at diagnosis were added as covariates to the multivariable model. CONCLUSIONS: The current study identifies PB blast percentage of ≥ 3% and platelet count of < 100 x 109/L, at presentation, as independent risk factors for LT in PMF. Unexpectedly, the study also revealed an association between LT and treatment history with ESA or danazol. These observations are intriguing, considering recent reports on the possible harmful effects of ESA in certain solid tumors.